

ABSTRACT OF THE DISCLOSURE

The invention provides a crystalline salt form of a novel β_2 adrenergic receptor
5 agonist. The invention also provides pharmaceutical compositions comprising the
crystalline form, formulations containing the pharmaceutical compositions, methods of
using the crystalline salt form to treat diseases associated with β_2 adrenergic receptor
activity, and processes useful for preparing such a crystalline compound.

10